ABSCIENCES (EPA:AB) | WebDisclosure

Basculer en Français

10161	Companies
208736	Keywords
138859	Articles
110648	Press releases

Home
Companies
ABSCIENCES

PRESS RELEASE

published on 10/16/2025 at 20:57, 5 months 20 days ago

AB Science provides intitial Phase 1 data for the combination of AB8939 with venetoclax for the treatment of refractory or relapsed acute myeloid leukemia
AB Science provides initial Phase 1 data for combination of AB8939 with Venetoclax for refractory or relapsed Acute Myeloid Leukemia. Promising results incl. 100% disease control rate and 100% response rate

AB Science AB8939 Phase 1 Data AML Venetoclax
PRESS RELEASE

published on 10/16/2025 at 20:57, 5 months 20 days ago

AB Science présente les premières données de phase 1 de la combinaison d’AB8939 et du venetoclax dans le traitement de la leucémie myéloïde aiguë réfractaire ou en rechute
AB Science présente les premières données de phase 1 de la combinaison d’AB8939 et du venetoclax dans le traitement de la leucémie myéloïde aiguë réfractaire ou en rechute. Des résultats prometteurs pour les patients atteints de LMA

Traitement AB Science AB8939 Leucémie Myéloïde Aiguë Venetoclax
BRIEF

published on 10/14/2025 at 08:41, 5 months 22 days ago

AB Science Reports Promising Initial Data from AML Study

Clinical Trial AML Treatment AB Science AB8939 Venetoclax
BRIEF

published on 10/14/2025 at 08:41, 5 months 22 days ago

AB Science publie des données initiales prometteuses issues d'une étude sur la LAM

Essai Clinique AB Science AB8939 Traitement De La LAM Venetoclax
PRESS RELEASE

published on 10/14/2025 at 08:36, 5 months 22 days ago

AB Science will hold a virtual conference on Thursday, October 16, 2025 from 2pm to 3pm CET to provide an update on the Phase 1 study with AB8939
AB Science releases positive initial data on combination treatment of AB8939 with Venetoclax for refractory or relapsed Acute Myeloid Leukemia (AML), showing promising results in patients with unfavorable genetic profiles. Virtual conference scheduled with renowned experts in AML

Virtual Conference AB Science AB8939 AML Venetoclax
PRESS RELEASE

published on 10/14/2025 at 08:36, 5 months 22 days ago

AB Science tiendra une conférence virtuelle le jeudi 16 octobre 2025, de 14 h à 15 h CET, afin de faire le point sur l'étude de phase 1 avec AB8939
AB Science publie les premières données de la combinaison de AB8939 avec Vénétoclax dans le traitement de la LMA, avec des résultats très encourageants. Une conférence virtuelle est prévue le 16 octobre 2025

Conférence Virtuelle AB Science AB8939 Venetoclax LMA
PRESS RELEASE

published on 10/10/2025 at 18:17, 5 months 26 days ago

Rapport financier semestriel 2025
BRIEF

published on 08/04/2025 at 08:03, 8 months 1 day ago

AB Science Completes EUR 2.55 Million Private Placement

Private Placement Shareholders Clinical Development AB Science EUR 2.55 Million
BRIEF

published on 08/04/2025 at 08:03, 8 months 1 day ago

AB Science finalise un placement privé de 2,55 millions d'euros

Actionnaires Placement Privé Développement Clinique AB Science 2,55 Millions D'euros
PRESS RELEASE

published on 08/04/2025 at 07:58, 8 months 1 day ago

AB Science announces the successful completion of a 2.55 million euros private placement
AB Science successfully completes EUR 2.55 million private placement to fund clinical development. New shares issued with warrants attached

Private Placement Shareholders Clinical Development AB Science EUR 2.55 Million

Accesswire

Published on 04/02/2026 at 22:00, 3 days 6 hours ago

Star Copper Announces Closing of Charity Flow-Through Unit Private Placement
Published on 04/02/2026 at 18:32, 3 days 9 hours ago

Datavault AI CEO Nathaniel Bradley to Present DataValue(R), DataScore(R), and Information Data Exchange(R) Technologies at XRP Tokyo 2026
Published on 04/02/2026 at 15:00, 3 days 13 hours ago

Jaguar Health Family Company Napo Pharmaceuticals Co-Sponsoring Pediatric Gastroenterology Conference: Elite Ped-GI Congress
Published on 04/02/2026 at 14:40, 3 days 13 hours ago

Northfield Capital Completes Acquisition Of Additional Interest In Juno Corp. And Announces Issuance Of Class B Multiple Voting Shares
Published on 04/02/2026 at 14:30, 3 days 13 hours ago

Worksport Announces COR(TM) Portable Energy System Is Now Fully Certified, Including Key UL and CSA Approvals, for North American Retail and Commercial Distribution

View all ACCESSWIRE

EQS Group

Published on 04/04/2026 at 10:07, 1 day 18 hours ago

Heidelberg Pharma to Present Data from its ADC Technology Platform at AACR Annual Meeting 2026
Published on 04/04/2026 at 02:05, 2 days 2 hours ago

Blokees made its debut at 2026 Thailand Toy Expo, exhibiting multiple products
Published on 04/03/2026 at 18:00, 2 days 10 hours ago

IEVA GROUP: IMPLEMENTATION OF A LIQUIDITY AGREEMENT WITH CREDIT INDUSTRIEL ET COMMERCIAL
Published on 04/03/2026 at 18:00, 2 days 10 hours ago

IEVA GROUP: MISE EN OEUVRE D’UN CONTRAT DE LIQUIDITE AVEC LE CREDIT INDUSTRIEL ET COMMERCIAL
Published on 04/03/2026 at 17:45, 2 days 10 hours ago

Atbash Launches on Chromia to Enable Verifiable, User-Controlled AI Systems

Les Echos

Published on 04/03/2026 at 18:46, 2 days 9 hours ago

Disclosure of Share Capital and Voting Rights as of March 31, 2026
Published on 04/03/2026 at 18:46, 2 days 9 hours ago

Déclaration du nombre d’actions et droits de vote au 31 mars 2026
Published on 04/03/2026 at 18:01, 2 days 10 hours ago

ALTAREIT : INFORMATION RELATIVE AU NOMBRE TOTAL DE DROITS DE VOTE ET D’ACTIONS COMPOSANT LE CAPITAL SOCIAL
Published on 04/03/2026 at 18:00, 2 days 10 hours ago

ALTAREA : INFORMATION RELATIVE AU NOMBRE TOTAL DE DROITS DE VOTE ET D’ACTIONS COMPOSANT LE CAPITAL SOCIAL
Published on 04/03/2026 at 18:00, 2 days 10 hours ago

LANSON-BCC : Déclaration du nombre total des droits de vote et du nombre d’actions au 31 mars 2026

View all LES ECHOS COMFI WIRE